Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion.
This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared reaction rates of 1-h maintenance infusions to that of 2-h maintenance infusions.
A total of 551 infusions were administered to 179 patients. The infusion groups demonstrated no significant differences in reaction rates.
Infliximab infusion over 1 h is well-tolerated.